M. M. Mahfouz, L. Li and M. Shamimuzzaman, “De Novo-Engineered Transcription Activator-Like Effector (TALE) Hybrid Nuclease with novel DNA Binding Specificity Creates Double-Strand Breaks,” Proceedings of the National Academy of Sciences of the United States, Vol. 108, No. 6, 2011, pp. 2623-2628. doi:10.1073/pnas.1019533108

has been cited by the following article:

• TITLE: New Gene Therapy Strategies for the Deletion of Exon 44 of Dystrophin Gene Based on Gene Editing by TALENs

  AUTHORS: Ping Li, Yunzhi Pan, Alice S. S. Li, Aijuan Sun, Jia Zhang, H. L. Gao, Pierre Sirois, Kai Li

  KEYWORDS: TALENs; DMD; Gene Therapy; Exon Skipping

  JOURNAL NAME: Open Journal of Medicinal Chemistry, Vol.3 No.1, March 29, 2013

  ABSTRACT: Duchenne Muscular Dystrophy (DMD) is a severe childhood form of muscular dystrophy. Both the severe form and its milder form of Becker Muscular Dystrophy (BMD) are caused by the mutation of dystrophin gene. Different from some other genetic diseases such as hemophilia that can be treated by replacement therapy, there is no effective therapy for muscular dystrophy in conventional medication. Gene editing technology from the recently developed engineered nucleases such as TALENs has been successfully employed in genome modification of a variety of species, and will be applied in gene therapy of selected human diseases. The genetic basis of DMD and BMD indicates that DMD is a good target for gene therapy through returning the reading frame of dystrophin gene. Gene therapy strategies described here may apply to many other genetic diseases. Wider application of TALENs in gene therapy have the potential to dramatically prolong the lifespan of individuals with genetic diseases.